$PFE Headlines Stock investors trash market darlings,

New Post Public Reply Private Reply Replies (0) Message Board

Jan 27, 2014 at 10:14 AM

$PFE Headlines

Stock investors trash market darlings, face Apple, Fed 8:00 a.m. Jan. 26, 2014 - Wallace Witkowski
Ken Fisher's new top stock picks 2:48 p.m. Jan. 21, 2014 - Insider Monkey
Audit: Medicare overpays for penis pumps 6:48 p.m. Jan. 14, 2014 - blogs.marketwatch.com
A contrarian take on the market’s correction 12:48 p.m. Jan. 9, 2014 - Mark Hulbert
Statin usefulness questioned, but patent expirations may ease pain 1:02 p.m. Jan. 8, 2014 - blogs.marketwatch.com
Cholesterol drugs: Do you need them, or not? 5:00 a.m. Jan. 8, 2014 - Elizabeth O'Brien
Buying the 2014 recovery 12:01 a.m. Jan. 7, 2014 - Jim Lowell
Dairy company Emmi acquires 50% stake in Mexideli 5:36 a.m. Jan. 3, 2014 - MarketWatch.com
10 stocks for the U.S. economy’s revival in 2014 10:14 a.m. Dec. 27, 2013 - Diana Furchtgott-Roth
Not all pharmaceuticals are created equal 12:39 p.m. Dec. 26, 2013 - The Trading Deck
Pfizer and Kaiser: They not only rhyme, they're in sync with workers 11:12 a.m. Dec. 10, 2013 - blogs.marketwatch.com
Safe and steady ETFs for the new year 12:03 p.m. Dec. 9, 2013 - Jim Lowell
Value investing for retirement portfolios 6:01 a.m. Dec. 7, 2013 - Robert Powell
Auxilium shares soar after FDA approves drug for additional use 3:53 p.m. Dec. 6, 2013 - blogs.marketwatch.com
A tale of two drug companies 4:13 p.m. Dec. 5, 2013 - Mark Hulbert
3 low-risk stocks for market skeptics 6:15 a.m. Dec. 5, 2013 - Jeff Reeves
DuPont, Pfizer are top decliners in Dow index 4:01 p.m. Dec. 3, 2013 - Polya Lesova
Large-caps can boost your portfolio at year-end 2:58 p.m. Nov. 22, 2013 - Mark Hulbert
Stock market live blog: S&P 500 record, Twitter options, China ETFs (Recap) 11:39 a.m. Nov. 18, 2013 - blogs.marketwatch.com
Bitcoin buying for dummies 3:22 p.m. Nov. 12, 2013 - blogs.marketwatch.com

Pfizer lung-cancer drug fails in two Phase III studies 7:26 a.m. Today - Seeking Alpha
MRK: Merck Stock a Strong Performer In the Pharma Space 3:00 a.m. Jan. 26, 2014 - InvestorPlace.com
Hey, Big Spender! 4:55 a.m. Jan. 25, 2014 - Barrons.com
5 New Drugs That Could Be Blockbusters in 2014 3:42 a.m. Jan. 25, 2014 - Barrons.com
Week Ahead: Fed Taper Decision, Earnings 5:11 p.m. Jan. 24, 2014 - FOXBusiness
Pfizer Inc (PFE): Today's Featured Drugs Laggard 5:01 p.m. Jan. 24, 2014 - TheStreet.com
Bristol-Myers Revenue Improves 1:27 p.m. Jan. 24, 2014 - WSJ.com
Turbocharged Dividends 8:05 a.m. Jan. 24, 2014 - Barrons.com
Earnings Fail to Impress the Market - Earnings Preview 3:41 a.m. Jan. 24, 2014 - Zacks.com
Drug Makers Tiptoe Back Into Antibiotics 5:10 p.m. Jan. 23, 2014 - WSJ.com
Will Bristol-Myers (BMY) Beat Q4 Earnings? - Analyst Blog 4:45 p.m. Jan. 23, 2014 - Zacks.com
Pfizer Reports Top-Line Results From ALO-02 Phase 3 Study; Meets Primary Endpoint 7:00 a.m. Jan. 23, 2014 - benzinga.com
More Great Dividend Stocks From Great Britain 6:29 a.m. Jan. 23, 2014 - Seeking Alpha
Athersys-Pfizer Investors: Anticipating A Phase III Trial For Inflammatory Bowel Disease 2:00 p.m. Jan. 22, 2014 - Seeking Alpha
Lpath Granted Key U.S. Patent Related to Ocular Drug Program, iSONEP 6:31 a.m. Jan. 22, 2014 - benzinga.com
Facebook Cements Position Among Most Traded Stocks 6:08 a.m. Jan. 22, 2014 - 247WallSt.com
Pfizer Finds Success With Chantix Clinical Study 7:44 p.m. Jan. 21, 2014 - Wall St. Cheat Sheet
Is Johnson & Johnson Enticing After Recent Headlines? 5:02 p.m. Jan. 21, 2014 - Wall St. Cheat Sheet
Will Pfizer Stop-Smoking Pill Hurt Tobacco Giants? 11:14 a.m. Jan. 21, 2014 - 247WallSt.com
Pfizer treatment to stop smoking meets endpoints 10:58 a.m. Jan. 21, 2014 - Seeking Alpha

Pfizer Announces Top-Line Results From Two Phase 3 Trials Of Dacomitinib In Patients With Refractory Advanced Non-Small Cell Lung Cancer 7:00 a.m. Today - BusinessWire - BZX
Pfizer Reports Top-Line Results From ALO-02 Phase 3 Study 8:00 a.m. Jan. 23, 2014 - BusinessWire - BZX
Pharmerging Markets 2012-2016 11:12 a.m. Jan. 22, 2014 - PR Newswire - PRF
New Survey Reveals What Match.Com Members Think About Smoking Cigarettes And Dating 10:00 a.m. Jan. 22, 2014 - BusinessWire - BZX
Lpath Granted Key U.S. Patent Related to Ocular Drug Program, iSONEP 7:30 a.m. Jan. 22, 2014 - PR Newswire - PRF
CHANTIX®/CHAMPIX® (varenicline) Demonstrates Smoking-Cessation Efficacy In Smokers Unwilling or Unable To Quit Abruptly 8:00 a.m. Jan. 21, 2014 - BusinessWire - BZX
ViiV Healthcare's new HIV medicine Tivicay™ (dolutegravir) is approved in Europe 6:52 a.m. Jan. 21, 2014 - PR Newswire - PRF
Statement from Pfizer Chief Medical Officer on the 50th Anniversary of the First Surgeon General's Report on Smoking and Health 10:15 a.m. Jan. 17, 2014 - BusinessWire - BZX
Collaborations, Conference Participation Schedules, and Upcoming Earnings Release - Research Report on Pfizer, Humana, WellPoint, Stryker, and Centene 8:00 a.m. Jan. 14, 2014 - PR Newswire - PRF
Companies Aligned to Capitalize on New Japanese Regenerative Medicine Initiatives 10:09 a.m. Jan. 13, 2014 - ACCESSWIRE
Portola Pharmaceuticals Enters Second Clinical Collaboration Agreement With Bristol-Myers Squibb and Pfizer to Study Andexanet Alfa* (PRT4445), Investigational Factor Xa Inhibitor Reversal Agent, With Eliquis 8:00 a.m. Jan. 13, 2014 - GlobeNewswire
Avillion Group Partners with Pfizer to Co-develop BOSULIF® (bosutinib) as First-Line Treatment for Patients with Chronic Myelogenous Leukemia 8:47 a.m. Jan. 9, 2014 - PR Newswire
Akili Interactive Labs Announces Partnership with Pfizer to Test Video Game in People at Risk of Alzheimer's Disease 8:03 a.m. Jan. 9, 2014 - PR Newswire
Health Care Sector Under the Lens: Pfizer, Merck & Co., AbbVie and Zogenix 8:00 a.m. Jan. 8, 2014 - PR Newswire
Nodality Enters into a Strategic Collaboration with Johnson & Johnson Innovation in Autoimmune Diseases 7:59 a.m. Jan. 8, 2014 - BusinessWire
Clinical Studies and Financial Results - Research Report on Pfizer, United Therapeutics, Insys, Puma Biotechnology, and Acorda 8:00 a.m. Jan. 1, 2014 - PR Newswire
Senesco Announces Letter of Intent to Merge with Fabrus 9:38 a.m. Dec. 30, 2013 - BusinessWire
Senesco Announces Letter of Intent to Merge with Fabrus 8:52 a.m. Dec. 30, 2013 - BusinessWire
Regulatory Submissions, New Clinical Trials, Results Scheduled, and Conference Calls - Research Report on Pfizer, Novartis, Teva, Universal Health Services, and BD 8:00 a.m. Dec. 24, 2013 - PR Newswire
Obesity Stock Plays Standing Out from the Crowd 10:04 a.m. Dec. 20, 2013 - ACCESSWIRE

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

The Chemical Industry and EPA: A Broken System?

Decades of an Unchecked Revolving Door The Environmental Protection Agency (EPA) and chemical manufacturers—a dance that’s been going on for what seems like forever. But not in the way you might hope. We're talking about a revolving door where execs and lobbyists waltz into regulatory chairs while regulators slide into cushy industry gigs. Wisner Baum LLP, a stickler...

Anecdotes by Artists Brings Raw Scent Stories to Sephora

When Maesa pulls back the curtain, they don't just crack it open—they fling it aside with flair. That's precisely what they're doing with their latest venture, Anecdotes by Artists, a fragrance brand that's taking its first bow exclusively at Sephora. It's not your average perfume launch; it's about the stories behind the scents and the artists who craft them. Unveiling...

FutureVault's AI Agents: Transforming Financial Workflows

Revolutionizing Financial Operations: FutureVault's AI Approach In the dizzying whirlwind of financial services, the launch of FutureVault AI Agents is a game-changer for document management. This isn't some half-baked tool; it's a full-fledged overhaul of how compliance and operations should tick in the modern age. We've all seen it—a paper trail tangled across systems...

HTX's Strategic Moves in Pakistan: A Crypto Frontier

Paving the Way: HTX's Journey in Pakistan Rolling into the Pakistan cryptocurrency scene isn't just a 'walk in the park' for HTX—it's more like traversing a new frontier with an open map. This isn’t some hit-and-run operation; HTX is strategizing for a long haul in one of the liveliest digital market arenas in South Asia. Gathering steam with community AMAs and an X...

Davos Healthcare Aims to Revolutionize Hospital Ratings

Throw away those dusty, old reputation surveys—Davos Healthcare just turned the spotlight onto cold, hard data with its new global hospital evaluation platform. Why Davos Healthcare’s Initiative Matters At the C3 US NYC Davos of Healthcare™ Summit, an event that’s rooted itself alongside the United Nations General Assembly, Davos Healthcare unveiled a...

Sean Trahan Joins Citrin Cooperman: New Tax Lead

Citrin Cooperman's Strategic Tax Move If there's one phrase that can spark a debate at a financial water cooler, it's 'transfer pricing.' Today, Citrin Cooperman is throwing its hat further into that ring with the appointment of Sean Trahan as head of their new Transfer Pricing and Value Chain Optimization Practice. This isn't just another reshuffling of office...

Succession Planning in Turmoil: Only 42% Ready

Diving into the Succession Crisis in Finance Succession planning in the financial advisory space is like retirement planning for the rest of us—everyone knows it's crucial, yet too many put it off. Despite the looming retirement wave and desperate interest from the younger cohort, a staggering 42% of financial advisors are still without a documented succession game...

UWM Faces Class Action Deadline: Key Insights for Investors

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

FJBio Boosts Antibody Discovery with Sapio AI

In the sprawling world of antibody discovery, where every scrap of data can make or break the next big breakthrough, FairJourney Bio (FJBio) is pulling out all the stops. They've teamed up with Sapio Sciences to ditch the paperwork nightmares and usher in a new era of AI-driven efficiency. With operations stretching from Porto to Cambridge to sunny San Diego, they’re...